Demographics of the study cohort
| All FTLD | bvFTD | nfvPPA | svPPA | PPA (lv/mixed) | PSP | CBS | |
| Total in catchment area (n) | 365 | 81 | 40 | 28 | 16 | 123 | 77 |
| Clinical phenotyping (n) | 310 | 64† | 36‡ | 25 | 16 | 101 | 68 |
| Age (mean years) (SD) | 70.26 (8.57) | 64.59 (9.56) | 72.09 (8.81) | 67.55 (6.43) | 70.80 (7.05) | 72.56 (7.14) | 72.08 (7.69) |
| Gender (male/female) | 152/158 | 33/31 | 15/21 | 14/11 | 7/9 | 56/45 | 27/41 |
| Symptom onset to study assessment (years, mean and SD) | 4.75 (3.18) | 5.70 (4.45) | 2.83 (1.93) | 4.96 (2.69) | 2.76 (1.97) | 4.50 (2.94) | 4.71 (2.77) |
| Diagnosis to study assessment (years, mean and SD) | 1.44 (2.77) | 1.88 (3.88) | 1.09 (1.27) | 1.65 (2.01) | 1.58 (1.67) | 1.02 (1.17) | 1.73 (2.02) |
| Symptom onset to death (years, mean and SD)* | 7.71 (4.37) | 9.08 (7.00) | 7.93 (3.47) | 11.03 (3.39) | 9.29 (3.14) | 6.39 (3.67) | 7.30 (3.12) |
| Diagnosis to care home (years, mean and SD)* | 2.94 (2.43) | 2.26 (2.90) | 4.43 (1.75) | 5.31 (1.86) | 4.44 (2.48) | 1.69 (1.20) | 3.13 (2.28) |
| Diagnosis to death (years, mean and SD)* | 4.40 (3.25) | 5.49 (5.06) | 5.50 (2.62) | 7.95 (2.61) | 5.74 (2.19) | 2.78 (2.7) | 4.12 (2.35) |
| Postmortem neuropathology | 53 | 8 | 4 | 5 | 1 | 16 | 19 |
| Pathology diagnoses | PiD=1 PSP=1 TDP=6 | CBD=3 AD=1 | PiD=1 TDP=4 | AD=1 | PSP=16 | CBD=6 AD=8 Other=3 |
*Subgroup of cohort with complete follow-up. Six patients were living in a care home at diagnosis.
†Twelve patients with bvFTD had motor neuron disease.
‡One patient with nfvPPA had motor neuron disease.
AD, Alzheimer’s disease pathology; CBD, corticobasal degeneration; PiD, Pick’s disease pathology; PSP, progressive supranuclear palsy pathology; TDP, 43 kDa Tar DNA binding portein, TDP43 pathology.